Teewinot Life Sciences Corporation, a Tampa, Florida-based company involved in discovery, development and commercialization of cannabinoid-based therapeutics and in the biocatalytic production of cannabinoids, closed a $12.3m Series B funding round.
The round was led by Tuatara Capital, a New York based private equity fund focused on investments in cannabis-related companies, which had led Teewinot’s $7m Series A round in December 2015.
The capital raised will be used for a variety of activities including enhancement and acceleration of research and development activities, expanding business development opportunities, and adding to the existing patent portfolio.
Teewinot Life Sciences is an international biopharmaceutical company focused on advanced pharmaceutical research and the use of novel biosynthetic processes such as biocatalysis and synthetic biology for cannabinoid manufacture.
Its proprietary production systems are being used to manufacture industrial quantities of a wide range of pharmaceutically pure cannabinoids including: CBGA, CBG, CBGVA, CBGV, THCA, THC, THCVA, THCV, CBDA, CBD, CBDVA, CBDV, CBCA, CBC, CBCVA, CBCV, CBN and CBL.